[Do glycopeptides remain the preferred treatment of nosocomial infections from multidrug resistant Staphylococcus?].
Brun-Buisson
C
C
CHU Henri-Mondor, 51 avenue du Maréchal-de-Lattre-de-Tassigny, 94100 Créteil, France. christian.brun-buisson@hmn.ap-hop-paris.fr
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy*; D018432:Drug Resistance, Multiple; D006020:Glycopeptides; D006801:Humans; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D006020:Glycopeptides